{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:35:46Z","timestamp":1791214546729,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":2625,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds231","type":"journal-article","created":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T03:42:47Z","timestamp":1348112567000},"page":"vii131-vii138","source":"Crossref","is-referenced-by-count":262,"special_numbering":"S7","title":["Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Berruti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Haak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds231_bb0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1093\/annonc\/mds231_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"International symposium on pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the first international symposium. October 2005","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Me tab"},{"key":"10.1093\/annonc\/mds231_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2008.10.006","article-title":"Pathogenesis of adrenocortical cancer","volume":"23","author":"Bertherat","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0025","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Esenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds231_bb0030","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0035","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds231_bb0040","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mds231_bb0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds231_bb0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12672-011-0094-2","article-title":"Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?","volume":"6","author":"Baudin","year":"2011","journal-title":"Horm Cancer"},{"key":"10.1093\/annonc\/mds231_bb0060","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"de Reyni\u00e8s","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds231_bb0065","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0070","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00423-011-0866-8","article-title":"Adrenocortical carcinoma: effect of hospital volume on patient outcome","volume":"397","author":"Lombardi","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"10.1093\/annonc\/mds231_bb0080","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2010.01.036","article-title":"Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer","volume":"57","author":"Porpiglia","year":"2010","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mds231_bb0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"key":"10.1093\/annonc\/mds231_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e3182367ac3","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma","volume":"255","author":"Reibetanz","year":"2012","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mds231_bb0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mds231_bb0100","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0105","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0110","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/cncr.24331","article-title":"Radiotherapy in adrenocortical carcinoma","volume":"115","author":"Polat","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds231_bb0115","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds231_bb0120","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1200\/JCO.2009.27.5958","article-title":"Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel","volume":"28","author":"Berruti","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds231_bb0125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds231_bb0130","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mds231_bb0135","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds231_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","article-title":"Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study","volume":"11","author":"Bukowski","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds231_bb0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1093\/annonc\/mds231_bb0150","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic 675 extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mds231_bb0155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"665 Clin Endocrinol (Oxf)"},{"key":"10.1093\/annonc\/mds231_bb0160","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419376616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_7\/vii131\/6675116\/mds231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:14:17Z","timestamp":1582179257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419376616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":31,"alternative-id":["S0923753419376616"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds231","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}